Novaliq’s Pipeline: Topical Therapies based on EyeSol
Anterior eye diseases (Dry Eye Disease)
| EyeSol® Product | Indication | Preclinics | Phase II | Phase III | NDA/MAA | Milestone(s) |
|---|---|---|---|---|---|---|
|
Vevizye® / Vevye® (ciclosporin ophthalmic solution, 0.1%) |
Dry eye disease (inflammatory) |
 Approved & partnered in: European Union, USA, UK, Australia, New Zealand
|
Approval in China Expansion to other ROW countries | |||
|
Miebo® / Heng Qin® (perfluorohexyloctane ophthalmic solution) |
Dry eye disease (evaporative) |
Approved & partnered in: USA, Canada, China
|
||||
Back of the eye diseases
| EyeSol® Product | Indication | |||||
|---|---|---|---|---|---|---|
|
NOV05 (tacrolimus in EyeSol®, solution) |
Uveitis, non-infectious |
Global
|
IND cleared by FDA Study started Q1 2026 |
|||
|
NQ-Retina (Peptides/NCEs) |
Diabetic Retinopathy (multimodal: anti-inflammatory, neuroprotective) |
Global
|
IND ready in 2027 | |||
|
NQ-ON (Peptides/NCEs) |
Undisclosed (multimodal) |
Global
|
IND ready in 2027 | |||